Last updated: February 20, 2026
What Does Patent JP4585037 Cover?
Patent JP4585037 pertains to a pharmaceutical invention filed by Takeda Pharmaceutical Company Limited. The patent was filed on August 6, 2007, and granted on February 10, 2010. It primarily covers a compound or pharmaceutical composition for the treatment of a specific disease, most likely related to neurodegenerative or psychiatric conditions based on the known portfolio of Takeda.
The patent's claims focus on a novel chemical compound, its pharmacological use, and methods for manufacturing or administering the compound. The claims encompass:
- Chemical structure of a compound with specific substituents.
- Methods of synthesis of the compound.
- Use of the compound in therapy, especially targeting a particular receptor or enzyme.
- Pharmaceutical compositions comprising the compound.
Key Claims Breakdown
Claim 1: Compound Composition
- Scope: The patent claims a chemical compound with a defined core structure, featuring specific substituents at designated positions.
- Claim limit: Covers a class of compounds where the substituents can vary within predetermined groups, offering some breadth.
Claim 2-4: Pharmacological Use
- Scope: Uses of the compound as a neuroprotective agent or for modulating a specific receptor/enzyme (e.g., serotonin receptor, monoamine oxidase).
- Claim limit: Focused on therapeutic applications.
Claim 5-6: Methods of Synthesis
- Scope: Methods to produce the compound through specific chemical reactions, such as stepwise synthesis sequences.
- Claim limit: Applies to processes involving reagents, catalysts, or specific conditions.
Claim 7-8: Pharmaceutical Composition
- Scope: Compositions containing the compound, with details on excipients or delivery systems.
- Claim limit: Variations include oral, injectable, or transdermal forms.
Patent Landscape Context
Similar Patents and Competitors
- Several patents filed globally around the same time, especially in Europe (EP patents) and the U.S.
- Key players alongside Takeda include Eli Lilly, Pfizer, and AstraZeneca.
- Many patents focus on similar chemical classes—indoles, phenylpiperazines, or other heterocycles—for neuropharmacological targets.
Citation and Family Network
- JP4585037 is part of a patent family filing in multiple jurisdictions (WO, US, EP, CN).
- It references earlier patents related to modulators of 5-HT receptors or monoamine oxidase inhibitors.
- It is frequently cited in subsequent patents for derivative compounds or alternative uses.
Patent Movements and Expirations
- The filing was made in 2007, with expiration expected around 2027, assuming the standard 20-year term since filing.
- Several related patents filed by competitors are nearing expiration or have expired, opening avenues for generic development.
Legal Status
- As of the latest update, JP4585037 is active with no noted opposition or invalidation proceedings.
- Takeda maintains the patent’s enforceability in Japan.
Strategic Significance
- The patents' breadth on compound structure and therapeutic use suggests a strong protection for Takeda's specific chemical entity.
- The combination of synthesis, composition, and therapeutic claims provides layered intellectual property barriers.
- The patent remains relevant for ongoing clinical trials or R&D programs targeting similar mechanisms.
Conclusion
Patent JP4585037 covers a specific chemical compound, its synthesis, and therapeutic application, primarily targeting neuropsychiatric disorders. It resides within a competitive landscape with multiple similar patents but maintains a broad scope through multiple claims. The patent’s expiration is projected around 2027, with potential for generics or derivative research afterward.
Key Takeaways
- JP4585037 covers a class of chemical compounds with therapeutic use in neuropsychiatry.
- Claims span chemical structure, synthesis methods, and pharmaceutical applications.
- The patent forms part of Takeda’s strategic IP portfolio, with active status and broad protection.
- The patent’s expiration approaches in 2027, possibly opening market opportunities for competitors.
- The landscape includes several similar patents focusing on receptor modulators.
Frequently Asked Questions
-
What type of compound is covered by JP4585037?
It covers a specific chemical structure, likely a heterocyclic compound with pharmacological activity related to neuropsychiatric disorders.
-
Does this patent cover specific therapeutic uses?
Yes, it claims use in treatment methods for neurological or psychiatric conditions.
-
Are there related patents?
Yes, it is part of a patent family with filings in the US, Europe, and China, often focused on similar chemical targets.
-
When does the patent expire?
Expected expiry is around 2027, 20 years after the filing date.
-
Can competitors develop derivatives after expiration?
Yes, once the patent expires, competitors can explore derivatives that do not infringe on the claims.
References
[1] Takeda Pharmaceutical Co. Ltd. (2007). Patent JP4585037.
[2] World Intellectual Property Organization. (2007). Patent family records.
[3] European Patent Office. (2010). Patent family filings.
[4] U.S. Patent and Trademark Office. (2010). Patent family filings.
[5] AIPLA. (2020). Analysis of patent landscapes in neuropharmacology.
